Update on novartis agreement

New york, dec. 13, 2021 (globe newswire) -- mesoblast limited (nasdaq:meso; asx:msb), global leader in allogeneic cellular medicines for inflammatory diseases, was notified today by novartis that it has chosen to terminate the agreement with mesoblast prior to closing. mesoblast remains highly focused on executing on our short term objective to bring remestemcel-l to market for patients with acute respiratory distress syndrome (ards) due to covid-19.
MESO Ratings Summary
MESO Quant Ranking